For instance, in the phase 2 PRINCE trial for metastatic pancreatic cancer, survival benefit with the CD40 agonist sotigalimab correlated with baseline immune signatures of an active APC compartment and robust CD4 + T cell infiltration [26]. This evidence concerns the gene CD4 and pancreatic neoplasm.